bêta
IA Trial Radar
L'essai clinique NCT05038852 pour Sevrage tabagique, Tabac est actif, pas en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Retour à la recherche

Acceptability of Mobile Applications (Apps) to Enhance Smoking Cessation in a Clinical Tobacco Treatment Program - A Pilot Study

Actif, pas en recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT05038852 est un essai interventionnel pour Sevrage tabagique, Tabac. Son statut actuel est : actif, pas en recrutement. L'étude a débuté le 12 avril 2019 et vise à recruter 8 participants. Dirigé par le Centre médical MD Anderson, l'essai devrait être terminé d'ici le 31 décembre 2025. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 29 juillet 2025.
Résumé succinct
We will conduct a small-scale randomized controlled trial (RCT) with 24 adult smokers enrolled in the TTP. Participants will receive either the Free4Good mobile app for positive psychology skills training or a breathing relaxation mobile app control (Breathe2Relax). All participants will be receiving tobacco cessation treatment in the Tobacco Treatment Program at MD Anderson as standard of care.
Description détaillée
The aims of this pilot protocol are to test the adherence, acceptability, user satisfaction, and preliminary efficacy of a smartphone mobile health app, Free4Good, which incorporates skills training in positive psychology vs. a relaxation app, Breathe2Relax (control condition), in a small randomized controlled trial of smokers (N = 24). Adherence will be measured directly through app usage data. Acceptability and user satisfaction will be measured via specific items included on a User Satisfaction Questionnaire. Efficacy outcomes include evidence of increased engagement in positive psychology-related quitting strategies (measured by the Quitting Strategies Questionnaire) and smoking abstinence.

Exploratory analyses including covariates such as nicotine dependence, mood, and depressive symptoms may be examined as appropriate, as these measures have been shown to predict abstinence outcomes in a variety of studies.1-4 Changes in mood and/or depressive symptoms may also be characterized

Titre officiel

Acceptability of Mobile Applications (Apps) to Enhance Smoking Cessation in a Clinical Tobacco Treatment Program - A Pilot Study

Conditions
Sevrage tabagiqueTabac
Autres identifiants de l'essai
  • 2018-0984
  • NCI-2021-09413 (Autre Identifiant) (NCI-CTRP Clinical Trials Registry)
Numéro NCT
NCT05038852
Date de début (réel)
2019-04-12
Dernière mise à jour publiée
2025-07-29
Date de fin (estimée)
2025-12-31
Inscription (estimée)
8
Type d'essai
Interventionnel
PHASE
N/A
Statut
Actif, pas en recrutement
Objectif principal
Prévention
Plan d'attribution
N/A
Modèle d'intervention
Groupe unique
Masquage
Aucun (ouvert)
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
AutreGroup 1 smartphone applications
app is designed to help you learn relaxation skills
Smartphone Applications
app is designed to help you learn relaxation skills.
Smartphone Applications
app is designed to help you increase your positive feelings, behaviors, and thoughts.
AutreGroup 2 smartphone applications
app is designed to help you increase your positive feelings, behaviors, and thoughts.
Smartphone Applications
app is designed to help you learn relaxation skills.
Smartphone Applications
app is designed to help you increase your positive feelings, behaviors, and thoughts.
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
To assess the adherence of a smartphone mobile health app.
through study completion, an average of 1 year
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
18 Years
Sexes éligibles
Tous
  • MD Anderson patient between the ages of 18 to 65
  • current smoker (i.e., at least 1 cigarette or e-cig per day)
  • smoking for at least one year,
  • willing to set a quit date in the next 30 days,
  • not engaged in smoking cessation treatment other than the MDACC Tobacco Treatment Program
  • English speaking and ability to read and comprehend English, and 7) currently own an iOS mobile phone (iPhone) using iOS 9.0 or later and reports regular use (at least weekly) of at least 1 iOS app.

  • endorsing current suicidal ideation or intent,
  • meeting criteria for a current Major Depressive Episode measured by the PHQ-9,
  • any medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator or Collaborator,
  • subject considered by the investigator an unsuitable candidate for receipt of a smoking cessation treatment or unstable to be followed up throughout the entire duration of the study.
  • Pregnant women will not be excluded from participating in the study and any decisions about potential pharmacotherapy will be done as standard of care in the Tobacco Treatment Program, including a consultation with the medical team and a joint decision-making process with the patient to determine the best course of treatment given all co-morbid medical conditions.
M.D. Anderson Cancer Center logoCentre médical MD Anderson1128 essais cliniques actifs à explorer
Aucune donnée de contact disponible
1 Centres de l'essai dans 1 pays

Texas

M D Anderson Cancer Center, Houston, Texas, 77030, United States